Effects of medium-chain triglycerides intake on mental health in elderly people
- Conditions
- Healthy elderly
- Registration Number
- JPRN-UMIN000045970
- Lead Sponsor
- Teikyo University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 45
Not provided
1.Patients with dementia 2.Patients being treated for diabetes mellitus, brain or heart diseases, and psychiatric disorders 3.People who are diagnosed with psychiatric disorders in the Mini-International Neuropsychiatric Interview 4.People who are on a low-carbohydrate diet or a ketogenic diet 5.People who daily take medicines or healthy foods that may affect cognitive function 6.People who daily take medium-chain triglycerides or coconut oil 7.People who have food allergies for milk or soybeans 8.People with lactose intolerance 9.People who have difficulty performing cognitive function and mental health tests 10.People with significant abnormalities in physical and blood tests 11.People who are positive for infectious diseases in blood test 12.People with 30 or more body mass index 13.People who participated in other clinical trials within 1 month before the start of this study, or people who plan to participate in other clinical studies within 12 weeks after the start of this study 14.People who are judged to be inappropriate by principal investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cognitive function(Trail Making Test, Stroop Test, Brief Assessment of Cognition in Schizophrenia) at baseline and after 12 weeks administration
- Secondary Outcome Measures
Name Time Method 1.Mini Mental State Examination 2.Beck Depression Inventory, State-Trait Anxiety Inventory, Hopkins Symptoms Checklist, Pittsburgh Sleep Quality Index 3.body weight, body mass index, skeletal muscle mass index, handgrip strength 4.blood inflammatory marker (C-reactive protein) milligram/dl 5.blood metabolites [medium-chain triglycerides(caprylic acid, capric acid), ketone bodies(beta-hydroxybutyric acid, acetoacetic acid)] microgram/ml 6.blood metabolic marker (ghrelin, des-acyl ghrelin, insulin-like growth factor-1,brain-derived neurotrophic factor) femtomol/ml at baseline and after 12 weeks administration